Events November 13, 2019 8:30 AM
Goodwin's Boston Office
100 Northern Avenue
Boston, MA

Jumpstart Bio: Public M&A in the Boardroom

Summary

Goodwin's Jumpstart Bio breakfast series gathers leaders in the Boston biotech and pharmaceutical community to discuss the intersection of science, business, and the law. This series equips drug development and commercialization professionals to anticipate, prepare for, and respond to issues on the horizon for the industry.

In the last 12 months, there have been 70 initial public offerings of healthcare, life sciences and medtech companies. In the coming months, we expect to see increased M&A activity surrounding these newly public companies. This program is designed to get you ready.

Public M&A in the Boardroom

Your recently IPO'd, now public, life sciences company has been in collaboration discussions with a big pharma company for your Phase 2 orphan drug candidate, Immuno-eradicate, the most mature asset in your pipeline. Unexpectedly, this big pharma company has submitted an unsolicited bid for the whole company, so your board is convening to figure out what to do…

A Goodwin team of M&A lawyers, including Partners Stuart Cable, Lisa Haddad, Jacqueline Mercier and Adam Slutsky will help direct you through the legal, business and practical pitfalls that public life science company boards routinely face in the wake of an unsolicited offer, to give you a preview of what could come if you find yourself faced with a bear hug from an interested buyer. Guests and the Goodwin team members will be assigned the roles of the public company target's board members, CEO, banker and lawyer, and you'll have to navigate the decision-making process as other guests will be assigned to various roles as your potential suitors, who will be submitting varying bids, some of which may include contingent value rights (CVRs) depending on the regulatory and commercial milestones reached by the Immuno-eradicate platform.

While it takes most companies several weeks or months to navigate through a public sale process, you'll sign up your transaction (or not) in only 60 minutes, while the Goodwin team helps to steer you through your fiduciary duties to shareholders, what to make of CVRs, the likelihood of and preparation for litigation, securities regulations, antitrust and special considerations for life sciences companies.

Wednesday, November 13, 2019
8:30 am - 9:00 am | Networking + Breakfast
9:00 am - 10:00 am | Program

Goodwin's Boston Office
100 Northern Avenue, 17th Floor | Boston, MA

To RSVP to this event, please click here.